Company intelligence / Profile preview

HCR Collateral Management

Ownership: Private
Development stage: Other

Overview

HCR Collateral Management is a provider of investment advisory services, specializing in identifying and acquiring premier healthcare assets, primarily royalty interests associated with marketed pharmaceutical products. The company invests in healthcare products with demonstrated, sustainable cash flows, often focusing on FDA-approved or near-commercialization therapeutics. It does not directly develop drugs, conduct R&D, or own clinical-stage product candidates.

Industry: Investors

Partnerships

RedHill Biopharma (Movantik royalty financing and debt extinguishment transaction)Coherus BioSciences (credit agreement)

Beyond the preview

Go deeper on HCR Collateral Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCR Collateral Management.

Explore the full profile